Blocking TGF-β signaling genetically (SMAD3−/−) and pharmacologically (anti-TGF-β antibody, 1D11) in mice lead to protective effects: decreased body weight gain and fat mass, improved insulin sensitivity, ameliorated hepatic steatosis. Here, INS is linked to fatty liver disease.